Skip Navigation LinksHome > March 2014 - Volume 21 - Issue 2 > New strategies for relapsed acute myeloid leukemia: fertile...
Current Opinion in Hematology:
doi: 10.1097/MOH.0000000000000018
MYELOID DISEASE: Edited by Martin S. Tallman

New strategies for relapsed acute myeloid leukemia: fertile ground for translational research

Dinner, Shira N.; Giles, Francis J.; Altman, Jessica K.

Collapse Box

Abstract

Purpose of review

Although frontline treatment of acute myeloid leukemia (AML) achieves high remission rates, approximately 75–80% of patients will either not respond to or relapse after initial therapy. Some patients, generally those who are younger, can be successfully salvaged with second-line chemotherapy followed by allogeneic stem cell transplantation. There is a great need for novel therapies in AML.

Recent findings

Advances in molecular technology recently identified recurrent mutations including mutations of DNMT3A, IDH1/2, and TET2. These mutations represent a major advance in the understanding of leukemogenesis and prognosis, and have enabled the development of targeted therapies.

Summary

Improved knowledge of the molecular pathogenesis of AML has allowed development of therapies targeting epigenetic modulation, intracellular signaling pathways, prosurvival proteins, and the tumor microenvironment.

© 2014 Wolters Kluwer Health | Lippincott Williams & Wilkins

Login

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.